title: Urinary trypsin inhibitor attenuated inflammatory response of patients undergoing cardiopulmonary bypass by inducing activated Treg cells.
abstract: The urinary trypsin inhibitor (ulinastatin) is used in the clinic to prevent inflammatory responses in patients undergoing cardiopulmonary bypass (CPB); however, the anti-inflammatory mechanism is unclear. In the current study, we recruited 40 patients undergoing selective cardiac valve replacement surgery; and these patients were randomly divided into two groups (ulinastatin group [UG] and control group [CG]). We collected peripheral blood preoperatively, at the end of CPB, and postoperative days 1 and 3 and analyzed the kinetic changes in regulatory T (Treg) cell subsets. There was no statistically significant difference in the number of CD4(+) T cells between the two groups. The number of CD4(+)CD25(+) Treg cells, especially the suppressive activated Treg (aTreg) subset, was higher in the UG than the CG 1 and 3 days postoperatively. Thus, ulinastatin alleviated the inflammatory response during CPB by inducing the expansion of aTreg cells.
authors.affiliation: Department of Extracorporeal Circulation, Center for Cardiac Intensive Care, Beijing Anzhen Hospital, Capital Medical University, No. 2 Anding Road, Chaoyang District, Beijing, 100029, China.
authors.forename: Xing
authors.initials: X
authors.lastname: Hao
authors.forename: Junyan
authors.initials: J
authors.lastname: Han
authors.forename: Zhichen
authors.initials: Z
authors.lastname: Xing
authors.forename: Yu
authors.initials: Y
authors.lastname: Hao
authors.forename: Chunjing
authors.initials: C
authors.lastname: Jiang
authors.forename: Jianping
authors.initials: J
authors.lastname: Zhang
authors.forename: Jing
authors.initials: J
authors.lastname: Yang
authors.forename: Xiaotong
authors.initials: X
authors.lastname: Hou
mesh_terms: D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count; D002315:Cardiopulmonary Bypass / Q000009:adverse effects*; D004311:Double-Blind Method; D005260:Female; D006023:Glycoproteins / Q000627:therapeutic use*; D006321:Heart; D019918:Heart Valve Prosthesis Implantation / Q000009:adverse effects*; D006801:Humans; D007249:Inflammation / Q000188:drug therapy* / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D010919:Placebos; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects / Q000276:immunology*
chemical_list: D000893:Anti-Inflammatory Agents; D006023:Glycoproteins; D010919:Placebos; C028665:urinastatin